Pyroptosis in NLRP3 inflammasome-related atherosclerosis
Xiang Zeng,
Dongling Liu,
Xia Huo,
Yue Wu,
Cuiqing Liu,
Qinghua Sun
Affiliations
Xiang Zeng
School of Public Health, International Science and Technology Cooperation Base of Air Pollution and Health, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou 310053, Zhejiang Province, China.
Dongling Liu
School of Basic Medical Science, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou 310053, Zhejiang Province, China.
Xia Huo
Laboratory of Environmental Medicine and Developmental Toxicology, Guangdong Key Laboratory of Environmental Pollution and Health, School of Environment, Jinan University, Guangzhou 511443, Guangdong Province, China.
Yue Wu
School of Public Health, International Science and Technology Cooperation Base of Air Pollution and Health, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou 310053, Zhejiang Province, China.
Cuiqing Liu
School of Public Health, International Science and Technology Cooperation Base of Air Pollution and Health, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou 310053, Zhejiang Province, China.
Qinghua Sun
School of Public Health, International Science and Technology Cooperation Base of Air Pollution and Health, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou 310053, Zhejiang Province, China.
Pyroptosis is a proinflammatory form of programmed cell death in response to inflammation. It involves in the pathogenesis and outcomes of atherosclerosis characterized by NLRP3 inflammasome assembly, membrane pore formation, cell swelling, pro-inflammatory mediator and cytokine release. There are known pyroptosis molecular pathways including the caspase-1 depended canonical signaling pathway and the caspase-4/5/11 determined non-canonical signaling pathway. It is essential to explore the connection among NLRP3 inflammasome, pyroptosis and atherosclerosis, which may shed light on the potential therapeutic strategies that target pyroptosis in atherosclerotic treatment.
